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The Possible Association of Byperuricemia 
and/or Gout with Diabetes Mellitus* 
By WILLIAM M. MIKKELSEN, M.D. 
University of Michigan Medical School 
Although the possibility of an association between gout and/or hyper- 
uricemia and diabetes mellitus was first suggested in the late 18th century,l 
the existence of such a relationship has yet to be conclusively established. 
The present report will review published data regarding the prevalence of 
gout and hyperuricemia in diabetic subjects, that of diabetes mellitus and 
impaired glucose tolerance in patients with gout, and will present pertinent 
data from the Tecumseh Community Health Study. 
In Table 24 are presented results of studies of the prevalence of gout in 
diabetic subjects. The results are quite divergent, ranging from an estimate 
of one case of concomitant gout in 1,500 cases of diabetes mellituss to as high 
as eight or nine per cent."." Most recent reports can be summarized as sug- 
gesting that the prevalence of gout in subjects with diabetes mellitus is 
relatively low. 
The occurrence of hyperuricemia in association with diabetes has also 
been reported. Several groups of i n ~ e s t i g a t o r s ~ ~ ~ ~  have reported the presence 
of hyperuricemia in patients in diabetic ketoacidosis, serum urate values re- 
verting to normal as the ketosis diminishes. There are conflicting reports, how- 
ever, regarding the prevalence of hyperuricemia in apparently controlled dia- 
betics (Table 25). In a small group of 18 diabetic subjects de Candial1 found 
hyperuricemia in 50 per cent. In a larger group of 258 patients Padova and 
Bendersky12 reported elevated serum urate values in approximately 25 per 
cent. In contrast to these reports Beckett and Lewisg found only 2.4 per 
cent of 800 diabetic subjects to be hyperuricemic. These authors also found 
the mean serum uric acid values for their diabetic subjects to be lower than 
those reported by others for nondiabetic subjects. 
Surveys of the prevalence of diagnosed diabetes mellitus in gouty patients 
(Table 26) have yielded values ranging from three14 to as high as eightlo per 
cent. One authority,lO however, states that in his series of gouty patients 
this combination is rare, occurring in only three individuals. This latter ex- 
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Table 24.-Prevalence of Gout in Diabetic Patients 
Authors Prevalence of Gout 
Contan? (1877) 
Grube3 (1895) 
Seckel4 ( 1925) 
Van Noorden and Ibaac? ( 1927) 
Rabinowitche ( 1928) 
Englehardt and Wagner’ (1950) 
Joslin, et a18 (1952) 
Beckett and Lewis9 (1960) 





“4 times chance” 
“Rare” 
“1 in 1500; rare” 
0.8% 
1.8% 
Table 25.-Prevalence of Hyperuricemia in Diabetic Patients 
Authors 
Prevalence of 
No. of Cases Hyperuricemia 
deCandia’1 ( 1930) 18 50.0% 
Beckett and Lewis9 (1960) 800 2.4% 
Padova and Bendersky12 ( 1962) 258 24.8% 
Table 26.-Prevalence of Diabetes in Gouty Patients 
Authors No. of Cases Prevalence of Diabetes 
Umber13 (1914) 278 5.4% 
Kuzell, et all* ( 1955) 504 3.0% 
Bartels, et all5 (1960) 500 3.8% 
Bendersky and Kreithenlo ( 1962) 8.0% 
Talbottl6 (1964) “Rare; only 3 cases 
in his series” 
perience is somewhat surprising since it suggests the possibility that gouty 
patients may actually have a lower prevalence of diabetes than the general 
population. 
With this possibility in mind, the recent experience at The University oi  
Michigan Hospital was reviewed (Table 27). Thus far in 1964, 21 new cases 
of primary gout have been encountered. In four instances glucose tolerance 
was not evaluated. In four a frankly diabetic glucose tolerance response 
was demonstrated. Of 12 cases in which only screening tests were performed, 
the results suggested “probable” diabetes ( fasting blood sugar greater than 
120 mg. per 100 ml. or 2 hour postprandial blood sugar greater than 180 
mg. per 100 ml. ) in five instances, “possible” diabetes ( 2  hour postprandial 
140-179 mg. per 100 ml.) in two, and were normal in five cases. One sub- 
ject, with a previous diagnosis of diabetes mellitus made elswhere, was found 
to have two normal fasting blood sugar values, but was noit further evaluated. 
Thus, over 50 per cent of this small group of gouty patients was found to 
have impaired carbohydrate tolerance although none would have been rec- 
ognized as diabetic without laboratory evaluation of glucose tolerance. This 
limited and uncontrolled experience does not warrant any firm conclusions, 
although it does suggest that carbohydrate tolerance is not uncommonly im- 
paired in gouty subjects. 
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Table 27.--New Cases of Primary Gout, 1964. The University of Michigan Hospital 
Total: 21 patients 
Sex: Male, 16 Female, 5 
Age: 20-72 years; 18 age 50 or over 
Diabetic Glucose Toleranre Test 
Diabetic Status 
4 pts. 











Table 28.-Preualence of Abnormal Carbohqdrate Tolerance in Gout 
Weiss, Segaloff and Moore17 143 28.0% 
19.0% 
“usual criteria” 21.0% 
“more rigid criteria” 12.0% 
controls 27 3.7% 
( 1957) controls 143 
Herman18 ( 1958) 82 
Two studies have been reported in which the carbohydrate tolerance of 
gouty subjects has been assessed in comparison with that of nondiabetic con- 
trols ( Table 28). Weiss, Segaloff and MooreI7 demonstrated abnormal glucose 
tolerance in 28 per cent of 143 gouty subjects matched for age, sex and 
degree of obesity. Hermanls found impairment of glucose tolerance, using 
rigid diagnostic criteria, in 12 per cent of 82 gouty subjects as contrasted 
to 3.7 per cent of 27 “ambulant, nongouty, arthritic patients.” 
Data from the Tecumseh Community Health Study of 1959-1960,19,20 
carried out under the direcjtion of Drs. Thomas Francis, Jr. and Frederick 
H. Epstein, were examined for evidence of an association between gout or 
hyperuricemia and diabetes mellitus. The subjects of this study represent 
a natural population unselected for any disease process. Technically satisfac- 
tory serum uric acid determinations were made for 6,000 subjects, utilizing 
the enzymatic spectrophotometric method of Liddle, Seegmiller and Las- 
ter.21 This presentation is concerned with the 85 per cent of study subjects 
20 years of age and over who had serum uric acid determinations. 
In Table 29 are presented the age and sex specific correlation coefficients 
between observed serum uric acid and blood sugar, serum cholesterol and 
observed and relative weight. It will be seen that there is little evidence of 
association between serum uric acid, blood sugar and serum cholesterol, al- 
though there is some suggestion of association between serum uric acid and 
acbAal and relative weights. 
The age and sex specific prevalence rates of diabetes mellitus, gout and 
coronary heart disease for study subjects 20 years of age and over for whom 
serum urate determinations were available are presented in Table 30. The 
overall prevalence of diabetes was 1.9 per cent, of gout 0.6 per cent and 
of coronary heart disease 4.4 per cent in this group of 4,015 subjects. Since 
there is an appreciable variation of serum urate values with sex and age,22 
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Table 29.-Age and Sex Specific Correlation Coeficients Between Observed 
Serum Uric Acid and Blood Sugar, Serum Cholesterol, Observed 
Weight and Relative Weight 
Correlation Coefficients (r) of Serum Uric Acid with: 
Age Group 
in Years Blood Sugar* Serum Cholesterol Observed Weight Relative Weight 
Males 
20-29 -0.046 0.087 0.144 0.195 
30-39 0.008 0.126 0.198 0.225 
4049  -0.054 -0.027 0.217 0.230 
50-59 -0.069 0.103 0.228 0.248 
60-69 -0.018 0.133 0.290 0.314 











































20-79 0.041 0.041 0.270 0.243 
Number of 
subjects 1263 2033 2035 2026 
“Following a modified glucose tolerance test in subjects who had eaten within 5 hours. 
Computations prepared by Dr. Mark Kjelsberg and Mr. Jacob Keller. 
individual serum urate values have been adjusted for this effect using the 
following formula: 
Observed serum Mean serum urate 
urate conc. of the less conc. of his age- 
individual subject sex-group + 4.5 mg. per 100 ml. 
Standard deviation of his age-sex-group 
= serum urate “score” 
This derived value, which corrects for age-sex differences in serum urate 
concentration, has been termed a “score” to differentiate it from the actual 
measured value. The “score,” then, is a statistical device by means of which 
an individual‘s serum urate concentration can be evaluated, or correlated 
with other data, in comparison with other persons of the same age-sex group. 
The mean serum urate scores of persons with diabetes mellitus, gout and 
coronary heart disease are indicated in Table 31. As would be expected, the 
highest value is observed in subjects with gout. Subjects with diabetes mel- 
litus have a mean value lower than the grand mean for all subjects of 4.5 
mg. per 100 ml., while subjects with coronary heart disease have an inter- 
mediate, somewhat elevated, mean value. Although these differences do 
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Table 30.-Age and Sex Specific Prevalence (%) of Coronary Heart Disease, 
Diabetes Mellitus and Gout in Persons 20 Years or Older for 
Whom Serum Uric Acid Scores Are Available 
Subjects Diagnosed as Having: 
Coronary Heart Diabetes 
Disease Mellitus Gout 
Number of 
Subjects % of % of % of 
Age Group with SUA Age Age Age 
in Years Scores Number Group Number Group Number Group 
Males 
20-29 39 1 3 0.8 0 - 1 0.3 
30-39 58 1 5 0.9 3 0.5 3 0.5 
40-49 407 15 3.7 5 1.2 3 0.7 
50-59 283 33 11.8 8 2.1 8 2.1 
60-89 188 31 18.7 9 5.4 0 
70 and over 111 20 18.0 7 8.3 1 0.9 
- 
20 and over 1939 ia7 5.5 30 1.5 14 0.7 
Females 
20-29 495 1 0.2 1 0.2 2 0.4 
30-39 590 1 0.2 3 0.5 2 0.3 
414 8 1.4 8 1.4 2 0.5 40-49 
50-59 281 18 8.4 10 3.8 3 1.1 
60-69 163 25 15.3 11 6.7 0 
70 and over 133 20 15.0 14 10.5 1 0.8 
20 and over 2076 71 3.4 45 2.2 10 0.5 
- 
Table 31.-Comparison of Mean Serum Uric Acid Scores of Persons with Coronary 
Heart Disease (CHD), Diabetes Mellitus and Gout 
SUA Scores 
(mg. per 100 ml.) 
Number of Standard 
Disease Classification Subjects Mean Deviation 
Without Regard to Combinations 
Coronary heart disease 178 4.72 1.123 
Diabetes mellitus 75 4.37 1.138 
Gout 24 5.61 1.574 
Subjects Having a Single Disease 
Diabetes 63 4.41 1.163 
Gout 20 5.60 1.671 
Subiects Having Two Disaasas 
CHD and diabetes 12 4.17 0.996 
CHD and gout 4 5.82 1.145 
Coronary heart disease 162 4.74 i . i i a  
not appear great, they are significant at the five per cent level at least by 
the “t” test. The mean scores, and the statistical significance of the differ- 
ences at the five per cent level, are essentially unchanged when subjects 
having multiple diagnoses are excluded. Finally, it will be observed that 
whereas twelve subjects had diabetes mellitus plus coronary heart disease and 
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four gout plus coronary heart disease, there were none with a diagnosis of 
both gout and diabetes mellitus. 
Presently available information does not suggest an increased prevalence 
of clinical gout in patients with diabetes mellitus. Although diabetic keto- 
acidosis may often be associated with temporary hyperuricemia, it is as yet 
uncertain how prevalent hyperuricemia is in subjects with well controlled 
or moderately controlled diabetes. The evidence suggests on the one hand 
that hyperuricemia may be present in 25 per cent or more of such subjects, 
and on the other that their mean serum urate values may be lower than 
normal. Reports of an apparently increased prevalence of hyperuricemia in 
diabetics should be examined critically in view of the many variables in- 
fluencing measurement of serum urate content, and of the difficulties in ar- 
riving at a satisfactory definition of hyperuricemia. There is a need for 
further studies in which serum urate values of diabetic and nondiabetic 
subjects are compared under controlled conditions. 
The weight of available evidence would suggest that diabetes mellitus is 
not a rare disease in patients with the diagnosis of gout, although it does 
not necessarily establish that it is higher than in nongouty subjects. When 
the two disorders coexist the diabetes is almost always of the mild, “maturity 
onset” variety. It is asymptomatic or latent, but capable of detection by 
presently accepted laboratory measurements of carbohydrate tolerance. Al- 
though the two controlled studies of carbohydrate tolerance in gouty pa- 
tients agree in suggesting an increased frequency of abnormality in subjects 
with gout, a word of caution is appropriate. Recent evidence from the Na- 
tional Health Surveyz3 indicates that the blood glucose levels after challenge 
with an oral glucose load increase with age. It is by no means certain that 
the diagnostic criteria accepted for healthy young adults are applicable to 
subjects over age 40 or 50. Since gout is encountered most frequently in the 
middle and later years of life, this is an important consideration. Further 
studies of carbohydrate tolerance in gouty and nongouty subjects carefully 
matched for age and sex (and, if possible, other factors such as obesity, etc.) 
are clearly indicated. 
Thus far, analysis of data from the Tecumseh Community Health Study 
has failed to establish the presence of an association of serum urate con- 
centration and blood sugar levels. Subjects with diabetes mellitus were 
found to have lower mean serum urate values than others in their age-sex 
groups. No subjeots were identified in whom both gout and diabetes mellitus 
existed. Although essentially negative, these results, based on a single 
examination of these subjects, do not rule out the possibility of such an 
association. 
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Discussion 
DR. BARTELS: We reported our studies of gouty patients wi,th diabetes in 
March, 1960, because Dr. Joslin had previously reported that the combination 
of gout and diabetes mellitus was extremely rare. 
In  a survey of 900 patients with gout, we found 29 patients had diabetes 
mellitus also. In most patients the diabetes developed after the gout. The 
two conditions developed simultaneously in only one patient, and in two 
cases diabetes developed after the patients had had gout for 5 and 17 years, 
respectively. Diabetes was found in 3.8 per cent of all patients with gout-a 
higher percentage than the 1.3 per cent incidence found in the average 
population. 
Recently, a new group of patients with gout was reviewed in which 27 
cases of diabetes mellitus were found, making the total number of patients 
with gout and diabetes observed to date 56. 
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An early clinical observation thought significant was that patients with 
recurring gout had no further gout attacks if diabetes developed. One patient 
had no further attacks for 15 years. Three patients who were observed for 
five years had no further attacks of gout. This observation led us to the 
possible conclusion that diabetes has an ameliorating effect on gout. In 
reviewing our figures in detail, 15 of the cases studied seem to support 
this conclusion. We realize that gout might take on a different pattern at 
different times, but in most of these patients the gout patterns were already 
well established. 
A total of 900 gouty patients was studied and 56 patients were found to 
have both gout and diabetes. These clinical observations were reported in 
the hope that others would test this clinical impression. We found the as- 
sociation between the two diseases to be fairly common, in contrast to Dr. 
Joslin’s findings which indicated a rare association of the two diseases. 
DR. MACLACHLAN: The first five gouty patients to be admitted to our 
Clinical Research Unit for studies previously described had abnormal glucose 
tolerance tests. In order to determine the frequency of this finding, 29 of our 
gouty patients who were being followed in the Rheumatism Clinic were 
given an oral tolerance test using 100 Gm. of glucose. No attempt was made 
to control the diets of these patients prior to the test and I have no informa- 
tion regarding the carbohydrate content of the diets. 25 of the 29 patients 
showed an abnormal response. This was characterized in almost all these 
cases by an elevated two hour value of 120 mg. per cent or higher, al- 
though the fasting level was usually normal. Only one of these patients was 
believed to have diabetes and was receiving tolbutamide. 
The control group, chosen randomly and matched by sex, age, and weight, 
was selected from patients who were attending general medical clinic. Al- 
though the study is still in progress, the results in 54 patients indicate an 
abnormal response to an oral glucose load in 40 per cent of these individuals. 
This percentage does seem to be quite high, but recently it has been 
pointed out that a decrease in carbohydrate tolerance, particularly in the 
older age group, is more common than we have thought. 
Many of our gouty patients were taking probenecid at the time the glucose 
tolerance test was carried out, but there were also a good many patients 
with abnormal responses to the test who were not receiving any drug. 
DR. ROBINSON: Dr. Maclachlan, were your patients given a test dose of 
glucose or was this two hours after a high carbohydrate meal? 
DR. MACLACHLAN: They were given a 100 Gm. glucose load after an over- 
night fast. Blood samples were taken in the fasting state and one half hour, 
one, two, and three hours after the test dose of glucose. 
DR. ROBINSON: Did you also wanlt to comment with respect to serum 
triglyceride levels in your gouty patients? 
DR. MACLACHLAN: At the time the glucose tolerance tests were performed, 
fasting blood samples were taken for measurement of serum triglyceride 
levels. It was noted that the mean value for triglyceride was lower in the 
control group of patients in general medical clinic than it was in the gouty 
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patients. The mean values were 116 mg. per cent in the 54 control patients 
and 144 mg. per cent in the 23 gouty patients. 
DR. WALLACE: Dr. Feldman's and my results'" are remarkably similar to 
those of Dr. Maclachlan. We were interested in the interrelationships be- 
tween gout and lipid abnormalities. We chose to select our patients with 
gout for the absence, as far as we could judge it clinically, of objective 
evidence of arteriosclerotic disease. These patients with gout, then, had no 
evidence of hypertension, coronary, cerebral or peripheral vascular disease, 
diabetes mellitus, or a wide variety of other conditions that imply arterio- 
sclerotic disease. Our controls were primarily husbands of clinic and hospital- 
ized patients and were healthy; the only selection was for the absence of 
arteriosclerotic disease and to match the age range of the gouty patients. 
The only significant difference between the gout and the control groups 
was in serum triglyceride. The mean serum triglyceride in the patients with 
gout was 142 mg. per 100 ml.; the mean for the healthy men was 100 mg. per 
100 ml. This difference was significant ( p  < 0.01). The frequency of elevated 
triglycerides was also much greater in the group of patients with gout than 
in the control group. Cholesterol and other lipid moieties studied did not 
differ significantly in the two groups. 
DR. ROBINSON: How large a number did you have in each group approx- 
imately, Dr. Wallace? 
DR. WALLACE: 34 gouty patients and 28 controls. 
DR. DECKER: I don't think Dr. Maclachlan gave the number of gouty pa- 
tients who showed elevated two hour glucose levels. 
DR. MACLACHLAN: There were 29 gouty patients and in 25 of these ab- 
normal glucose levels were found. 
DR. DECKER: In response to a glucose tolerance test? 
DR. MACLACHLAN: Yes. 
DR. WALLACE: I must say that in our group we did not study this so their 
normal carbohydrate was defined as a normal fasting blood sugar not as a 
glucose tolerance test. 
DR. MACLACHLAN: That is interesting because in many of our patients 
with gout the fasting blood glucose level was normal. 
DR. DECKER: Were they receiving medication? 
DR. MACHLACHLAN: Yes, many of them were receiving probenecid and 
DR. WALLACE: None of our patients were on any medication. 
DR. DECKER: Salicylates? 
DR. MACHLACHLAN: o. 
DR. HALL: I want to make a few remarks about diabetes. Our findings are 
essentially the same as Dr. Mikkelsen's. The mean serum uric acid level in 110 
diabetics was the same as in the population at risk and the mean post meal 
blood sugar was the same in the gouty patients as it was in the population at 
risk. 
colchicine. 
*Feldman, E. and Wallace, S.: Hypertriglyceridemia in Gout, Ciiculntion 29:508, 1964. 
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I think that one has to be very careful, especially in dealing with per- 
centages and a small number of patients, to test for significance. The report, 
for example, by Weiss et al, is not significant and looking at the one by 
Herman it appears to me that that would not be a significant statistical dif- 
ference either. I think that all we can say is that our findings, which were 
based not on glucose tolerance tests but were post meal blood sugars, did not 
show any assocation. 
None of our gouty patients had diabetes. There were 4 hyperuricemics in 
110 diabetics, over 7.0 mg. per cent serum uric acid level, that is. 
DR. DECKER: Could Dr. Mikkelsen give us the mean SUA scores for the 
entire population from which Table 31 is drawn. Maybe I’ve missed that. 
DR. MIKKELSEN: It was 4.5. The score, as I said previously, is an attempt 
to correct the individual serum uric acid value for the age and sex variations 
that seem to be present in the Tecumseh population. It is a statistician’s 
device. Essentially what it does is to attempt to consider serum uric acid 
value for each individual in comparison with other individuals of the same 
age and sex group. I think in general it is apparent that our data are very 
much like Dr. Hall’s in that in adults the levels don’t vary greatly, except in 
females at an age period that would seem to correspond with the meno- 
pause. There are very significant changes in children, but that’s not pertinent 
in this group. 
DR. ROBINSON: What is your normal for fasting blood sugar, Dr. Mac- 
lachlan? 
DR. MACLACHLAN: 100 mg. per cent. 
DR. ROBINSON: What would you say the average fasting blood sugar was 
DR. MACLACHLAN: 90-95 mg. per cent. 
DR. SEEGMILLER: I’d like to ask Dr. Bartels if his patients with gouty 
arthritis and diabetes were in an older age group than the nondiabetic sub- 
jects with gouty arthritis. 
in your group of patients? 
DR. BARTELS: A study of that kind was not done. 
DR. ROBINSON: Further questions? 
DR. GUTMAN: Dr. Bartels, is your group of gouty patients under treat- 
ment with uricosuric agents eating a lot more than they used to before they 
were being treated in this way? 
DR. BARTELS: I can only say that most of them are overweight. For in- 
stance, all of the last group that we have studied-this new 27 that we have 
since 1960-all of these patients are overweight. That’s the only thing I 
can answer about that. 
DR. GUTMAN: The reason I ask is, ever since the uricosuric agents came 
in, the diet in our own group has been I think unduly liberalized, so when you 
compare your group after 1955, let’s say, your 1960 group with a group before 
the introduction of uricosuric drugs there may appear to be a large increase 
in the number of diabetic subjects encountered recently. 
DR. Yu:  What is the incidence of a family history of diabetes in those who 
developed manifest diabetes. 
DR. BARTELS: I’m sorry I can’t give you those figures. 
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DR. ROBINSON: One might express the feeling that in studies of this type, 
if we take any particular point in time we may not obtain a complete or 
accurate picture. These are diseases that take time to develop. Observations 
of patient groups, or population groups, over a period of time will be neces- 
sary in order to get some idea of the possible correlations. 
Before we terminate the discussion, we might mention the problem of 
hyperuricemia in relation to psoriasis and the relationship of sarcoidosis to 
hyperuricemia. 
DR. SEEGMILLER: There is no unanimity of opinion regarding the exact 
incidence of hyperuricemia in psoriasis. Dr. Eisen became interested in this 
at the National Institutes of Health and we did some studies of the incorpo- 
ration of glycine-C14 into urinary uric acid in a group of patients who have 
psoriasis. The major finding was a maximal incorporation of isotope into 
urinary uric acid around the 3rd to 4th day, in contrast to the peak on the 
1st cir 2nd day found in patients with primary gout, or on the 12th to 15th 
day as observed in patients with secondary gout associated with mylo- 
proliferative diseases. We thought the maximum incorporation on the 3rd 
to 4th day reflected the increased proliferation of the epidermis involved in 
formation of psoriatic scales. 
We did a study on one woman who showed overincorporation of glycine 
into uric acid at a time when she was suffering from an exacerbation of 
her psoriasis. This returned to the normal range and pattern when she was 
studied during a remission from her psoriasis. We did one study in a pa- 
tient who had both gout and psoriasis and in this situation the pattern of 
incorporation was more that of primary gout than of psoriasis. Perhaps 
psoriasis is one more condition that can contribute to an increase in uric 
acid production. 
DR. ROBINSON: Were the patients in whom these incorporation studies 
were carried out hyperuricemic? 
DR. SEEGMILLER: Yes, moderately hyperuricemic except for the study on 
the woman after remission whose serum urate had returned to the normal 
range. 
DR. ROBIVSON: What has been your experience in managing patients with 
gout who happen to have psoriasis? 
DR. SEEGMILLER: The patients with gout and psoriasis that we have had 
occasion to treat happen to have had fairly mild psoriasis which has re- 
sponded well to topical ointments. The gout responded as would be expected 
to uricosuric drugs and colchicine. The patients with more severe psoriasis 
and psoriatic arthritis studied by Dr. Bunim’s group responded to metho- 
trexate therapy but they still regard this as strictly an experimental approach 
to study of the disease rather than a recommended form of therapy. 
DR. SORENSEN: I may mention also a case we had of primary gout and 
psoriatic arthritis in the same patient, who also had a strongly positive sero- 
logical reaction for rheumatoid arthritis. Now, apparently this patient had a 
typical incorporation peak-your patient had two of primary incorporation. 
He  is now entirely free of skin symptoms but still excretes a tremendous 
amount of uric acid in the urine, so I think this is quite clearly primary gout. 
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The most interesting thing is that he had gone to a dermatologist for ap- 
proximately 25 years and had extensive lesions, nearly all over his body, but 
since his uric acid in the plasma fell to the normal range, he has been free 
of psoriasis. He’s not receiving any local treatment to the skin. 
DR. MCCARTY: I have another case of psoriatic arthritis and gout and it 
is remarkable. He is a physician, so we have a very good history of his at- 
tacks and other symptoms. He has two distinct histories; one is chronic, 
with occasional remissions and exacerbations, but the fluid retained in the 
joints, even though he was hyperuricemic at the time, had no crystals in it; 
this chronic form does not respond to phenylbutazone or colchicine. Super- 
imposed on this he has acute attacks and has crystals with the acute at- 
tacks and these are responsive to colchicine. 
DR. WYNGAARDEN: We see quite a lot of sarcoid at Duke and have never 
systematically analyzed these patients, but just on informal statistics kept on 
the ward, I’d say roughly one-fourth of these patients have a serum uric 
acid of 7.0 mg. per cent or above. This is by the clinical chemistry method, 
which agrees within 0.2 mg. per cent with our enzymatic method. We have 
looked at a few of the 24 hour excretions of uric acid in these patients and 
they’ve always been within normal limits. We’ve never done any clearance 
studies on them or any isotope studies. 
A few of these patients have been given chlorothiazide for one reason or 
another, and the serum uric acid rose still higher. We have then seen at- 
tacks which were clearly gouty, and colchicine responsive. As you know, the 
patient with sarcoidosis is also prone to other types of joint attacks, both 
acute and chronic, and these are frequently difficult to diagnose, especially 
the more acute ones. I think now that we have the opportunity of looking 
at the joint fluid more systematically we should be able to solve these prob- 
lems. We have sometimes treated such attacks with colchicine with a feeling 
that they responded. There is also Dr. Kaplan’s report of partial responses 
to colchicine and others who claim partial responses. 
DR. RODNAN: Has anyone found crystals in the joint fluid from sarcoid 
arthritis? 
DR. MCCARTY: This has not been reported, to my knowledge. 
